Whole Body Vibration in Progressive Multiple Sclerosis in Patients with Gait Disorder

Whole Body Vibration in Progressive Multiple Sclerosis in Patients with Gait Disorder - WBV in PMS

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00022962

Enrollment

Registered

2020-08-31

Start date

2020-09-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G35.3 G35.9

Interventions

Group 1: Arm 1: Whole Body Vibration Group home training program with a standardised training protocol (10x/week, 4x2 minutes, week 1-12) followed by no training (week 13-24) Group 2: Arm 2: Standard

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Men and women capable of giving informed legal consent aged between 18-70 years, diagnosed with progressive multiple sclerosis who have either no immunomodulatory therapy or have been stable for 6 months at their therapy, who display a gait disorder (EDSS 4-6,5)

Exclusion criteria

Exclusion criteria: 1. pregnancy (secure and safe contraception must be used) Safe conceptive are means with a Pearl-Index smaller than 1 %: a. Oral contraceptives b. Dermal hormonal contraceptives c. Vaginal hormonal contraceptives (NuvaRing®) d. contraceptive dermal patch e. longterm contraceptive shots (injectable) , f. Progesteron releasing contraceptive implants (Implanon®), g. tubal ligation, tying of the fallopian tubes (female sterilisation ), h. hormone releasing contraceptive coil (IUD, contraceptive intrauterine device ), i. double barrier methods Not reliable and unsafe are condom and spermicide, single barrier methods (condom, copper intrauterine device, basal temperature method, coitus interrupts, cervical clap, female condom, contraceptive sponge) 2. acute thrombosis 3. Implants in trained limbs (artificial hip, knee replacement) 4. bone fractures 5. not being able to give legal informed consent 6. not being able to exercise (immobility, NYHA IV)

Design outcomes

Primary

Measure	Time frame
6 minute walking distance, measured at baseline (before start of training), end of week 12 (after 12 weeks of WBV training or standard) and end of week 24 (after another 12 weeks with no training or WBV training)	—

Secondary

Measure	Time frame
MAS, EDSS, Spacticity Score, clinical markers Timepoints: at baseline, after 12 weeks and after 24 weeks	—

Countries

Germany

Contacts

Public ContactMonika Höveler

Uniklinik Köln Studienbüro Neurologie

monika.hoeveler@uk-koeln.de+49 221 478-87353

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026